^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:Breast Cancer
    Drug:MEN1611 (PI3K inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

    Excerpt:
    ...- Advanced or metastatic breast cancer harbouring PIK3CA mutation on tissue sample...
    Trial ID:
    B-PRECISE-01
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Cancer Res
    Title:

    The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations

    Excerpt:
    Tumors harboring PIK3CA mutations were significantly sensitive to CH5132799 in vitro and were remarkably regressed by CH5132799 in in vivo mouse xenograft models. In combination with trastuzumab, tumors disappeared in the trastuzumab-insensitive breast cancer model with the PIK3CA mutation.
    DOI:
    10.1158/1078-0432.CCR-10-2882